UK Markets closed

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
46.73+0.34 (+0.73%)
At close: 4:00PM EDT
46.73 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close46.39
Open46.50
Bid42.52 x 1000
Ask47.90 x 1200
Day's range46.45 - 46.88
52-week range30.10 - 49.07
Volume203,258
Avg. volume346,076
Market cap30.533B
Beta (5Y monthly)0.59
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

    Company Announcement Net sales of DARZALEX® in the third quarter of 2021 totaled USD 1,580 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 19, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were U

  • Globe Newswire

    Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy

    Media ReleaseCopenhagen, Denmark, October 15, 2021 Janssen-Cilag International NV (Janssen) received a positive CHMP opinion recommending conditional marketing authorization of amivantamab in Europe for the treatment of adult patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations, after failure of platinum-based therapyRepresents First CHMP opinion for a DuoBody® product candidate Genmab A/S (Nasdaq: GMAB) announced today th

  • Globe Newswire

    Grant of Restricted Stock Units and Warrants to Employees in Genmab

    Company Announcement COPENHAGEN, Denmark; October 7, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 18,689 restricted stock units and 21,537 warrants to employees of the company and three of the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the